XXXX for Treatment of Genital Infantile Hemangioma.

@entity1 @entity1169 @entity455 @entity2695 @entity7492 @entity4053 @entity551 @entity1168
PURPOSE: Genital @entity7492 are @entity455 that often require complex management and interdisciplinary care. @entity1169 was first used to treat @entity1 with @entity7492 in 2008 and has since gained acceptance as first-line therapy. MATERIALS AND METHODS: We review the presentation, course, management and outcomes of all cases of genital @entity7492 managed by @entity1169 administration at a single institution from April 2010 to July 2014. RESULTS: During the study period 9 @entity1 with genital @entity7492 were referred to our @entity2695 treatment clinic. @entity1169 was initially administered under careful outpatient monitoring at a dose of 1 mg/kg daily in  8  @entity1 . One @entity1 , a 700 gm premature @entity1 , was started on therapy in  the inpatient setting at 0.5 mg/kg daily, given the history of prematurity. All @entity1 underwent successful increase of dose to at least 2 mg/kg for the observation phase after tolerating the starting doses. One @entity1 discontinued @entity1169 prematurely per parental request due to concern regarding peripheral vasoconstriction. Otherwise, no @entity1 demonstrated significant @entity551 , symptomatic @entity1168 , @entity4053 or other major side effect requiring treatment discontinuation. All @entity1 who continued the treatment protocol had excellent response to therapy. CONCLUSIONS: @entity1169 therapy for genital @entity7492 was successfully initiated and the dosage increased in 9 young @entity1 without significant side effects and with marked improvement in all @entity1 who continued on  treatment. @entity1169 is the only Food and Drug Administration approved therapy for treatment of @entity1 with this @entity455 and should be considered first-line therapy for genital @entity7492 .
